Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lupin Offloads Kyowa For $525m But Not Exiting Japan

$300m Net From Deal Gives Leeway For Acquisitions, Organic Growth

Executive Summary

Lupin plans to invest in acquisitions and organic growth in the US and India after selling Japanese subsidiary Kyowa Pharma for an enterprise value of around $525m to Japan private equity group Unison Capital. But the Indian firm stresses it is not exiting Japan and will continue to look for marketing partnerships.

You may also be interested in...



Lupin Builds On Chinese Ambitions With Yabao Alliance

Lupin has built on a recent alliance in China with Foncoo by agreeing a further partnership for the Chinese market, this time with Yabao Pharmaceutical.

Lupin Signs First Chinese Partnership With Foncoo

Lupin has partnered with Chinese firm Foncoo Pharmaceutical to begin supplying its portfolio of generic medicines to the region. At the same time, it has also acquired a number of brands from fellow Indian drug manufacturer Anglo-French Drugs & Industries Limited.

Lupin Awaits 'Clarity' On Albuterol Filing

After lower growth in its India business and impaired operations at five manufacturing units hit by US FDA action impacted Lupin's third-quarter revenues, one-offs sent its net profit crashing. While deferring reinspection timelines for its Goa and Somerset plants, the company remains confident of adding at least 15 products to its US portfolio in FY21.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB149345

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel